Kura Oncology Stock Forecast

Stock Price Forecast

According to 16 analysts polled by S&P Global, Kura Oncology stock has a consensus rating of "Strong Buy" and an average price target of $31.85. The average 1-year stock price forecast is 318.53% higher than the current stock price, while the lowest is $15 (+97.11%) and the highest is $76 (+898.69%).

Price Target: $31.85 (+318.53%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$15	$31.85	$28	$76
Change	+97.11%	+318.53%	+267.94%	+898.69%

Analyst Ratings

The average analyst rating for Kura Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	May '26	Jun '26	Jul '26	Aug '26	Sep '26	Oct '26
Strong Buy	12	12	12	12	12	12
Buy	2	2	2	2	2	3
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	15	15	15	15	15	16

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jason Zemansky Bank of America Securities	Bank of America Securities	Buy Maintains $31	Buy	Maintains	$31	+307.36%	Oct 30, 2026
David Dai UBS	UBS	Buy Maintains $15	Buy	Maintains	$15	+97.11%	Oct 29, 2026
Priyanka Grover J.P. Morgan	J.P. Morgan	Buy Maintains $30	Buy	Maintains	$30	+294.22%	Oct 14, 2026
Daniel Brims Lake Street	Lake Street	Buy Reiterates $23	Buy	Reiterates	$23	+202.23%	Sep 10, 2026
Unknown Analyst Leerink Partners No rating	Leerink Partners	Buy Maintains $12	Buy	Maintains	$12	+59.66%	Sep 10, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

96.49M

from 67.48M

42.98%

from 67.48M

Revenue Next Year

209.06M

from 96.49M

116.68%

from 96.49M

EPS This Year

-3.17

from -3.18

EPS Next Year

-2.34

from -3.17

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	53.88M	67.48M	96.49M
Revenue Growth	-	-	-	-	25.24%	42.98%
Operating Income	-131.26M	-139.87M	-165.80M	-193.20M	-303.63M	-309.82M
Net Income	-130.47M	-135.84M	-152.63M	-173.98M	-278.67M	-294.30M
EPS	-	-	-	-	-3.18	-3.17
Free Cash Flow	-	-	-	-	-70.70M	-317.00M
No. Analysts	-	-	-	-	-	15

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	139.4M
Avg	96.5M
Low	80.7M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	106.6%
Avg	43.0%
Low	19.6%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-2.96
Avg	-3.17
Low	-3.48

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-